Lamivudina Accord (Lamivudine)

Lamivudine is a nucleoside analogue that is converted inside cells to its active triphosphate form. This active metabolite competes with natural nucleotides for incorporation into viral DNA by reverse transcriptase, causing premature chain termination and preventing viral replication.

The appropriate dose of lamivudine is determined by the prescribing healthcare professional based on the specific indication, patient weight, renal function, and other clinical factors. Dosage regimens may differ between HIV and hepatitis B treatment, and the prescriber will provide individualized instructions.

Safety data for lamivudine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be discussed with a qualified clinician.

To order Lamivudina Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, similar to drugs such as tenofovir and abacavir. Compared with tenofovir, lamivudine generally has a lower risk of renal toxicity but may be less potent in some HIV regimens. Choice of agent depends on resistance patterns, comorbidities and individual patient factors.

Lamivudina Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in humid or excessively hot environments.

Lamivudina Accord is administered orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, unless otherwise directed by the prescriber. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events associated with lamivudine include lactic acidosis, severe hepatomegaly with steatosis, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should seek immediate medical attention if they experience unexplained fatigue, abdominal pain, rapid weight loss, or any severe rash.

Lamivudina Accord should not be used by individuals with a known hypersensitivity to lamivudine or any of its excipients. Caution is also advised in patients with severe hepatic impairment or those with pre‑existing mitochondrial disorders, as the risk of serious adverse reactions may be increased.